Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.
Full description
This study is designed to evaluate the efficacy and safety of omecamtiv mecarbil in reducing the risk of the primary composite endpoint of cardiovascular (CV) death, first heart failure (HF) event, left ventricular assist device (LVAD) implantation, cardiac transplantation, and stroke in patients with symptomatic heart failure with severely reduced ejection fraction (HFrEF).
Eligible patients will be randomized 1:1 to investigational product (IP) - omecamtiv mecarbil or placebo. The study is event-driven and will conclude when at least 850 participants experience a HF event or CV death, whichever comes first. An interim analysis for futility and efficacy based on the primary composite endpoint is planned when approximately 570 (67%) of the planned 850 first HF events or CV deaths are observed.
Estimated duration of participation: Up to 3 years.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Adult patients who meet all the following criteria at screening may be included in the study:
Are between ≥ 18 years and ≤ 85 years at the signing of informed consent
Have a history of chronic HFrEF, defined as requiring treatment for HF for a minimum of 3 months prior to screening
Are receiving oral loop diuretics
Patients without AFF on screening ECG:
Patients with AFF on screening ECG:
Are currently hospitalized with the primary reason of HF, or had an HF event within 6 months prior to screening
Are established on regional standard-of-care HF therapies for at least 30 days prior to screening
Systolic blood pressure ≤ 130 mmHg and diastolic blood pressure ≤ 90 mmHg
Exclusion criteria
Any of the following criteria will exclude potential patients from the study:
Primary purpose
Allocation
Interventional model
Masking
1,800 participants in 2 patient groups, including a placebo group
There are currently no registered sites for this trial.
Central trial contact
Cytokinetics MD
Start date
Dec 19, 2024 • 4 months ago
Today
May 01, 2025
End date
Sep 01, 2027 • in 2 years
Lead Sponsor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal